Literature DB >> 33731842

Potential drug-drug interactions of antiretrovirals and antimicrobials detected by three databases.

Pornpun Vivithanaporn1, Teetat Kongratanapasert2, Bovornpat Suriyapakorn3, Pichayut Songkunlertchai3, Patpicha Mongkonariyawong3, Patanachai K Limpikirati4, Phisit Khemawoot5,6.   

Abstract

Standard treatment for HIV infection involves a combination of antiretrovirals. Additionally, opportunistic infections in HIV infected patients require further antimicrobial medications that might cause drug-drug interactions (DDIs). The objective of this study was to to compare the recognition of DDIs between antiretrovirals and antimicrobials by three proprietary databases and evaluate their concordance. 114 items of antiretrovirals and antimicrobials from the National List of Essential Medicines of Thailand 2018 were used in the study. However, 21 items were not recognised by Micromedex, Drugs.com, and Liverpool HIV interactions. Only 93 items were available for the detection of potential DDIs by the three databases. Potential DDIs detected from the three databases included 292 pairs. Liverpool showed the highest number of DDIs with 285 pairs compared with 259 pairs by drugs.com and 133 pairs by Micromedex. Regarding the severity classifications, Liverpool reported 10% Contraindicated; Micromedex reported 14% contraindicated and 59% major; Drugs.com reported 21% major. The Fleiss' kappa agreements were fair to poor among the three databases, higher agreement was observed for DDIs classified as severe. This study highlights the need to harmonize the evaluation and interpretation of DDI risk in order to produce standardized information to support prescribers.

Entities:  

Year:  2021        PMID: 33731842      PMCID: PMC7971054          DOI: 10.1038/s41598-021-85586-8

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  31 in total

Review 1.  Drug metabolism and variability among patients in drug response.

Authors:  Grant R Wilkinson
Journal:  N Engl J Med       Date:  2005-05-26       Impact factor: 91.245

2.  Clinically significant drug interactions in younger and older human immunodeficiency virus-positive patients receiving antiretroviral therapy.

Authors:  Pannyun Yiu; Nancy N Nguyen; Mark Holodniy
Journal:  Pharmacotherapy       Date:  2011-05       Impact factor: 4.705

3.  Mortality after failure of antiretroviral therapy in sub-Saharan Africa.

Authors:  Olivia Keiser; Hannock Tweya; Paula Braitstein; François Dabis; Patrick MacPhail; Andrew Boulle; Denis Nash; Robin Wood; Ruedi Lüthi; Martin W G Brinkhof; Mauro Schechter; Matthias Egger
Journal:  Trop Med Int Health       Date:  2009-12-09       Impact factor: 2.622

4.  Analysis of drug-drug interactions among patients receiving antiretroviral regimens using data from a large open-source prescription database.

Authors:  Nimish Patel; Peter Borg; Richard Haubrich; Ian McNicholl
Journal:  Am J Health Syst Pharm       Date:  2018-06-14       Impact factor: 2.637

Review 5.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

Review 6.  Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting.

Authors:  Kay Seden; Saye H Khoo; David Back; Pauline Byakika-Kibwika; Mohammed Lamorde; Mairin Ryan; Concepta Merry
Journal:  J Antimicrob Chemother       Date:  2012-08-22       Impact factor: 5.790

7.  Addressing Antiretroviral Therapy-Associated Drug-Drug Interactions in Patients Requiring Treatment for Opportunistic Infections in Low-Income and Resource-Limited Settings.

Authors:  Daniel B Chastain; Carlos Franco-Paredes; Kayla R Stover
Journal:  J Clin Pharmacol       Date:  2017-09-08       Impact factor: 3.126

8.  Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.

Authors:  Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding
Journal:  JAMA       Date:  2018-07-24       Impact factor: 56.272

9.  Predictors of Time to First Line Antiretroviral Treatment Failure among Adult Patients Living with HIV in Public Health Facilities of Arba Minch Town, Southern Ethiopia.

Authors:  Bilcha Oumer Enderis; Sultan Hussen Hebo; Mesfin Kote Debir; Negussie Boti Sidamo; Mulugeta Shegaze Shimber
Journal:  Ethiop J Health Sci       Date:  2019-03

Review 10.  The natural history of HIV infection.

Authors:  Caroline A Sabin; Jens D Lundgren
Journal:  Curr Opin HIV AIDS       Date:  2013-07       Impact factor: 4.283

View more
  3 in total

1.  Clinical standards for the dosing and management of TB drugs.

Authors:  J W C Alffenaar; S L Stocker; L Davies Forsman; A Garcia-Prats; S K Heysell; R E Aarnoutse; O W Akkerman; A Aleksa; R van Altena; W Arrazola de Oñata; P K Bhavani; N Van't Boveneind-Vrubleuskaya; A C C Carvalho; R Centis; J M Chakaya; D M Cirillo; J G Cho; L D Ambrosio; M P Dalcolmo; P Denti; K Dheda; G J Fox; A C Hesseling; H Y Kim; C U Köser; B J Marais; I Margineanu; A G Märtson; M Munoz Torrico; H M Nataprawira; C W M Ong; R Otto-Knapp; C A Peloquin; D R Silva; R Ruslami; P Santoso; R M Savic; R Singla; E M Svensson; A Skrahina; D van Soolingen; S Srivastava; M Tadolini; S Tiberi; T A Thomas; Z F Udwadia; D H Vu; W Zhang; S G Mpagama; T Schön; G B Migliori
Journal:  Int J Tuberc Lung Dis       Date:  2022-06-01       Impact factor: 3.427

2.  Characteristics of 2-drug regimen users living with HIV-1 in a real-world setting: A large-scale medical claim database analysis in Japan.

Authors:  Daniel J Ruzicka; Mayuko Kamakura; Naho Kuroishi; Nobuyuki Oshima; Miyuki Yamatani; Jingbo Yi; Bruce Crawford; Kunihisa Tsukada; Shinichi Oka
Journal:  PLoS One       Date:  2022-06-14       Impact factor: 3.752

3.  Evaluation of the Potency of Anti-HIV and Anti-HCV Drugs to Inhibit P-Glycoprotein Mediated Efflux of Digoxin in Caco-2 Cell Line and Human Precision-Cut Intestinal Slices.

Authors:  Martin Huličiak; Ivan Vokřál; Ondřej Holas; Ondřej Martinec; František Štaud; Lukáš Červený
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.